Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $21.33.

NRIX has been the subject of several research reports. Wells Fargo & Company cut their price target on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. HC Wainwright decreased their price objective on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Robert W. Baird boosted their target price on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. Morgan Stanley increased their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 9th.

Nurix Therapeutics Trading Up 0.4 %

NASDAQ:NRIX opened at $12.78 on Monday. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $18.12. The firm has a market capitalization of $628.15 million, a price-to-earnings ratio of -4.80 and a beta of 2.10. The business’s 50-day moving average price is $13.86 and its two-hundred day moving average price is $9.98.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.04. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The firm had revenue of $16.59 million for the quarter, compared to analysts’ expectations of $14.58 million. Sell-side analysts predict that Nurix Therapeutics will post -3.15 earnings per share for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,499 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the completion of the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 13,705 shares of company stock worth $154,012. 7.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. ARK Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 23.2% during the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after acquiring an additional 601,952 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in Nurix Therapeutics by 176.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after acquiring an additional 440,112 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Nurix Therapeutics by 48.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after acquiring an additional 184,617 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Nurix Therapeutics by 1,012.4% in the third quarter. GSA Capital Partners LLP now owns 195,420 shares of the company’s stock worth $1,536,000 after purchasing an additional 177,852 shares during the last quarter. Finally, Kennedy Capital Management LLC increased its position in Nurix Therapeutics by 192.7% during the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after acquiring an additional 107,719 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.